Skip to content

Comparing the effect of immunotherapy with hydroxychloroquine and vitamin D3

Comparative study of the effect of immunotherapy with hydroxychloroquine and vitamin D3 compared to vitamin D3 alone in patients with recurrent miscarriage

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20250507065634N3
Enrollment
80
Registered
2025-08-24
Start date
2025-09-17
Completion date
Unknown
Last updated
2025-09-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: Recurrent Pregnancy Loss. Condition 2: Spontaneous abortion. Pregnancy care for patient with recurrent pregnancy loss Spontaneous abortion

Interventions

Intervention 1: Control group: They will receive oral vitamin D3 1000 units daily after a positive pregnancy test and confirmation of intrauterine pregnancy with serial pregnancy tests or vaginal ultr

Sponsors

Mashhad University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 40 Years

Inclusion criteria

Inclusion criteria: Women between the ages of 18 and 40 Women who are trying to conceive Women with a history of at least two consecutive first-trimester miscarriages of unknown origin, with normal parental karyotype, absence of uterine abnormalities associated with recurrent miscarriage Normal serum vitamin D levels (above 30) and less than 100 Consent to participate in the study

Exclusion criteria

Exclusion criteria: Pregnancy at the time of study entry Normal pregnancy since last miscarriage Antiphospholipid syndrome with persistently positive APL antibodies and the presence of clinical conditions of APS based on Myakis criteria Known contraindications for the use of hydroxychloroquine or vitamin D Other chronic diseases History of epilepsy or psychotic disorders History of recent use of hydroxychloroquine or vitamin D in the past two months

Design outcomes

Primary

MeasureTime frame
Frequency of ongoing pregnancy. Timepoint: Week 20 onwards. Method of measurement: Ultrasound.

Secondary

MeasureTime frame
Repeated miscarriage. Timepoint: Before week 20. Method of measurement: Fetal loss before 20 weeks with Ultrasound.;Gestational age at the time of miscarriage. Timepoint: Number of weeks of pregnancy. Method of measurement: Ultrasound.;Fetal abnormalities. Timepoint: Weeks 6-8, 11-13, 18-22 of pregnancy. Method of measurement: Ultrasound.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactShaghayegh Jahantigh

Mashhad University of Medical Sciences

jahantigh.sh71@gmail.com+98 936 600 3045

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026